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Abstract
Objective: Serum levels of retinol-binding protein 4 (RBP4), an adipokine thought to 
affect systemic insulin sensitivity, were compared between women with polycystic ovary 
syndrome (PCOS) and non-PCOS controls to evaluate the association of RBP4 with 
clinical, hormonal and metabolic parameters of PCOS.
Subjects and methods: Serum RBP4 levels were analysed in 278 women with PCOS (age 
range 18–57 years) and 191 non-PCOS controls (age 20–53 years) by enzyme-linked 
immunosorbent assay.
Results: Serum levels of RBP4 were increased in women with PCOS compared with 
control women in the whole population (45.1 ± 24.0 (s.d.) vs 33.5 ± 18.3 mg/L, P < 0.001). 
Age-stratified analysis showed that serum RBP4 levels were increased in women with 
PCOS aged ≤30 years compared with controls (47.7 ± 23.5 vs 27.1 ± 10.4 mg/L, P < 0.001), 
whereas no significant differences were seen in the other age groups. No significant 
correlations of RBP4 were seen with either steroids or indices of insulin resistance.
Conclusions: Although serum RBP4 levels were increased in younger women with PCOS 
compared with age-matched non-PCOS controls, RBP4 does not seem to be a good marker 
of insulin resistance or other metabolic derangements in women with PCOS.
Introduction
Polycystic ovary syndrome (PCOS) is the most common 
endocrine disorder in women of reproductive age, with an 
estimated prevalence of 6–15%, depending on the criteria 
used for diagnosis (1). It is a heterogeneous disorder with 
several metabolic and cardiovascular health implications. 
Women with PCOS commonly suffer from chronic 
anovulation, infertility, hyperandrogenaemia, obesity, 
dyslipidaemia and low-grade chronic inflammation (2). 
Insulin resistance is a common feature of PCOS and 
women with the syndrome are more insulin resistant than 
expected for their BMI (3). Furthermore, the presence 
of central obesity has a detrimental effect on insulin 
resistance levels.
The aetiology of PCOS is multifactorial and complex. 
It is postulated that adipose tissue dysfunction plays a 
significant role in the metabolic abnormalities observed 
in affected women (4). Though several studies have been 
carried out to investigate the possible role of various 
adipocytokines in the pathogenesis of PCOS (5, 6, 7), 
it is not clear whether they have a direct association 
with PCOS. Adipose tissue acts as an endocrine organ 
secreting various adipokines including retinol-binding 
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protein 4 (RBP4), which is mainly synthesised by 
hepatocytes and adipose tissue. RBP4 is an adipokine with 
a possible detrimental effect on insulin sensitivity. Indeed, 
RBP4 is thought to act via alterations in insulin signalling 
in muscle, inhibiting glucose uptake and interfering with 
insulin-mediated suppression of glucose production in 
the liver (8, 9).
Studies have shown that circulating RBP4 levels 
correlate with the magnitude of insulin resistance in 
obese subjects and in those with impaired glucose 
tolerance and type 2 diabetes mellitus (10, 11). However, 
data concerning the circulating concentrations of RBP4 
in women with PCOS are conflicting. Besides unchanged 
levels of RBP4, increased as well as decreased levels have 
been reported. Elevated levels of RBP4 have been observed 
in both lean and overweight/obese women with PCOS 
(12), while one study revealed higher RBP4 levels only in 
obese women with PCOS (13). In contrast, lower levels 
of RBP4 have been reported in lean women with PCOS 
(14) whereas other investigators have found no difference 
in the concentrations of RBP4 in women with PCOS 
compared with BMI-matched controls (15, 16). Results 
concerning an association between serum RBP4 levels 
and insulin resistance in PCOS have also been conflicting, 
as a few investigators have reported no association (14, 
15) while others have reported that RBP4 levels correlate 
positively with insulin resistance, but not PCOS per se (17, 
18). Up to now there have been no studies in which the 
levels of RBP4 at different ages during reproductive life 
in women with PCOS vs non-PCOS women have been 
compared.
The aim of the present study was to compare the 
serum levels of RBP4 in women with PCOS vs non-PCOS 
women at different ages during reproductive life and to 




The study population consisted of 278 women with PCOS 
(age range 18–57 years) and 191 non-PCOS controls (age 
20–53 years) who participated in six Nordic PCOS studies: 
four studies in Finland and two in Sweden (19, 20, 21, 22, 
23, 24). PCOS was diagnosed according to the European 
Society of Human Reproduction and Embryology/American 
Society for Reproductive Medicine (ESHRE/ASRM) 
consensus definition (25). Ovarian morphology was 
assessed by means of transvaginal ultrasonography in all 
subjects. Biochemical hyperandrogenism was defined as 
serum testosterone ≥2.3 nmol/L, according to the upper 
limits of the accredited laboratory at Oulu University 
Hospital (NordLab) in fertile-aged women, and clinical 
hyperandrogenism (hirsutism) was diagnosed when a 
subject had a Ferriman–Gallwey (FG) score >7. Accordingly, 
women with polycystic ovaries (PCOs) in ultrasonography, 
oligo-amenorrhoea (OA) and hyperandrogenism (HA) 
(serum testosterone ≥2.3 nmol/L and/or FG score of >7) 
constituted 31.7% of the whole PCOS group, women with 
PCO and OA 60.4%, women with PCO and HA 4.7% and 
women with OA and HA 3.2%. Thus, 39.6% of women 
with PCOS were hyperandrogenic and 60.4% were 
normoandrogenic.
The control population consisted of women with 
normal appearing ovaries as assessed by ultrasonography 
and absence of PCOS-related symptoms (oligo- or 
amenorrhoea and/or hirsutism and/or elevated serum 
testosterone levels). Women using hormonal preparations 
and medications affecting glucose metabolism and steroid 
synthesis were excluded from the study. Alternatively, a 
washout period of 2  months was required for women 
using hormonal preparations before participating in 
the study. The diagnosis of pre-existing diabetes was an 
exclusion criterion in all studies, so none of the study 
subjects had type 2 diabetes. The samples were collected 
in a fasting state on any day of the menstrual cycle. A 2-h 
oral glucose tolerance test (OGTT) was carried out in 234 
women with PCOS and in 109 non-PCOS controls. Fasting 
and two-hour glucose and insulin concentrations were 
measured after a 75 g glucose load. In the control group, 
92.8% of the women had normal glucose tolerance (NGT) 
(fasting plasma glucose (FPG) ≤5.5 mmol/L or 2 h OGTT 
glucose <7.8 mmol/L) and 7.2% had impaired fasting 
glucose ((IFG); FPG 5.6–6.9 mmol/L) or impaired glucose 
tolerance ((IGT); 2 h OGTT glucose 7.8–11.0 mmol/L). 
In the PCOS group, 81.8% had NGT and 18.2% 
IFG/IGT. Informed consent was obtained from each 
subject after full explanation of the purpose and nature 
of all procedures used, and the study was approved by the 
Ethics Committee of Oulu University Hospital.
Methods
Serum levels of RBP4 were analysed by enzyme-linked 
immunosorbent assay according to the manufacturer’s 
instructions (Quantikine ELISA; R&D Systems). The intra- 
and inter-assay coefficients of variation were 6.5 and 9% 
respectively. The metabolic variables (androstenedione (A), 
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dehydroepiandrosterone sulphate (DHEAS), glucose, 
insulin, cholesterol, lipoproteins, triglycerides and high-
sensitivity C-reactive protein) were analysed by means of 
routine methods used in the laboratories of the different 
study sites (22, 23, 24). Of note, the number of subjects 
varied between analyses owing to a lack of measurements 
in some cases. Serum concentrations of testosterone and 
sex hormone-binding globulin (SHBG) were analysed 
by means of liquid chromatography-mass spectrometry 
and chemiluminometric immunoassay, respectively, at 
Nordlab, Oulu, as reported earlier (26). The free androgen 
index (FAI) was calculated as testosterone/SHBG (both as 
nmol/L) × 100. Mean OGTT plasma glucose and serum 
insulin levels were calculated as the means of concentrations 
at different time points ((basal + 2-h)/2). Insulin resistance 
was defined by the homeostasis model assessment of 
insulin resistance (HOMA-IR) and insulin sensitivity by 
evaluating the composite insulin sensitivity index (ISI) or 
the Matsuda index as described earlier (27, 28).
Statistical analysis
Statistical analyses were performed using SPSS 25.0 software 
(IBM Corp.). Variables with a skewed distribution were 
logarithmically transformed before statistical analysis. 
Differences between the PCOS and control groups were 
assessed using independent-samples t-tests. Adjustment 
for age and BMI was carried out by means of univariate 
general linear modelling using age and BMI as covariates. 
To evaluate the hormonal and metabolic changes 
with regard to age, the PCOS and control groups were 
grouped as follows: ≤30 years, 31–40 years and 41 years 
to menopause. One-way analysis of variance (ANOVA) 
with Tukey post hoc tests was used to assess the age-related 
changes of RBP4 between different age groups. Pearson’s 
correlation coefficients were used to assess the correlation 
between RBP4 and different variables, and adjustment for 
age and BMI was carried out by way of partial correlation 
analyses. Values of P < 0.05 were considered statistically 
significant.
Results
Characteristics of the study population
All anthropometric and metabolic parameters of the study 
population are shown in Table 1. Women with PCOS had 
a higher BMI compared with the controls. After adjusting 
for age and BMI, the levels of testosterone, FAI and A were 
significantly higher and those of SHBG lower in the PCOS 
group compared with the controls. Furthermore, women 
with PCOS had higher levels of triglycerides, fasting 
glucose, 2-h OGTT insulin and mean OGTT insulin and 
lower Matsuda indices compared with the non-PCOS 
controls after adjustment for age and BMI.
Clinical, hormonal and metabolic variables in the 
different age groups are shown in Table  2. The levels 
of testosterone, FAI, A, DHEAS and triglycerides were 
significantly higher and those of SHBG lower in women 
with PCOS aged ≤30 years compared with controls in the 
same age group after adjusting for BMI. In the age group 
of 31–40 years, the levels of testosterone, FAI, A, fasting 
glucose, 2-h OGTT insulin and mean OGTT glucose 
were higher in the PCOS group after adjusting for BMI. 
Furthermore, the waist-hip ratio (WHR) and the FAI were 
significantly higher in women with PCOS in the age group 
of 41 years to menopause.
Serum levels of RBP4 based on age and 
BMI stratification
In the whole study population, the concentrations of RBP4 
were increased in the PCOS group compared with controls 
after adjusting for age and BMI. Age-stratified analysis 
showed that this increase in serum RBP4 levels was observed 
only in women with PCOS aged ≤30 years compared with 
controls, but not in the other age groups (Table 2), and 
this was also the case after adjustment for BMI. One-way 
ANOVA indicated that serum concentrations of RBP4 
increased with age up to menopause in the control group 
(P < 0.001), whereas the levels remained unchanged in 
women with PCOS (P = 0.106) (Fig. 1). When the subjects 
were divided into different BMI groups (normal weight 
<25 kg/m2, overweight 25–30 kg/m2 and obese >30 kg/m2), 
the concentrations of RBP4 were increased in both lean 
and overweight women with PCOS after adjusting for age 
(Fig.  2). Furthermore, a subanalysis was performed after 
excluding women with PCOS aged over 46 years as these 
women exhibited lowered androgen levels. The results 
were similar to those found in the whole study population 
(data not shown).
Serum levels of RBP4 based on phenotype, androgen 
status and glucose tolerance
Serum RBP4 levels were increased in women with PCOS 
in the PCO + OA + HA and PCO + OA phenotype groups 
when compared with the control women (Fig.  3A). 
Furthermore, women with PCO + OA + HA had increased 
levels of serum RBP4 levels when compared with those 
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with PCO + OA. These results remained significant even 
after adjustment for age and BMI. The RBP4 levels in the 
other two phenotypes (PCO + HA, OA + HA) could not 
be statistically compared with others as the numbers of 
subjects in these groups were few.
Serum levels of RBP4 were increased in both 
normoandrogenic and hyperandrogenic women with 
PCOS when compared with the control women after 
adjusting for age and BMI (Fig. 3B). Women with PCOS 
and NGT had higher levels of serum RBP4 when compared 
with controls with NGT (Fig. 3C), whereas no statistically 
significant differences were observed in the IFG/IGT 
subjects (Fig. 3D). Further, no differences were found in 
the serum levels of RBP4 in the NGT vs IFG/IGT controls, 
which was also the case in women with PCOS (data 
not shown).
Correlation analyses
Serum concentrations of RBP4 were weakly negatively 
correlated with levels of serum fasting glucose in the 
PCOS group after adjustment for age and BMI (r = −0.229, 
P < 0.001). No significant correlations with either steroids 
or lipids were observed in the whole PCOS group. In the 
control group, levels of RBP4 were positively correlated 
with age (r = 0.376, P < 0.001). No other statistically 
significant correlations were seen in the control group 
after age and BMI adjustment.
In women with PCOS aged ≤30 years, levels of RBP4 
were positively correlated with WHR (r = 0.193, P = 0.020) 
and triglyceride levels (r = 0.685, P = 0.001) and negatively 
correlated with fasting glucose levels (r = −0.252, P = 0.002) 
after BMI adjustment.
Discussion
The present study showed that serum RBP4 levels were 
higher in young women with PCOS (≤30  years of age) 
when compared with their age-matched non-PCOS 
controls. Furthermore, RBP4 levels remained unchanged 
with age in the PCOS group while in control women they 
increased up to menopause.
Conflicting results have been reported as regards 
levels of RBP4 and its role in the pathogenesis of PCOS and 
Table 1 Clinical, hormonal and metabolic parameters in control women and women with polycystic ovary syndrome.
Parameter
Control PCOS
P value P value adjusted*n Mean (s.d.) n Mean (s.d.)
Age (years) 191 33.0 (9.2) 278 32.4 (7.9) 0.511 –
BMI (kg/m2) 191 24.8 (4.9) 278 27.1 (5.7) <0.001 –
WHR 191 0.80 (0.07) 278 0.82 (0.08) 0.028 0.901
Systolic BP (mmHg) 178 117 (13) 269 120 (15) 0.027 0.337
Diastolic BP (mmHg) 178 73 (10) 269 75 (11) 0.040 0.396
Testosterone (nmol/L) 191 0.9 (0.4) 278 1.4 (0.6) <0.001 <0.001
SHBG (nmol/L) 191 56.2 (24.1) 278 46.6 (22.8) <0.001 0.008
FAI 191 2.0 (1.4) 278 3.5 (2.2) <0.001 <0.001
Androstenedione (nmol/L) 92 7.9 (4.4) 223 14.8 (8.4) <0.001 <0.001
DHEAS (μmol/L) 58 3.9 (1.8) 223 4.8 (2.7) 0.050 0.188
Total cholesterol (mmol/L) 176 4.5 (0.9) 106 4.8 (1.0) 0.013 0.803
HDL (mmol/L) 176 1.6 (0.3) 106 1.5 (0.4) 0.549 0.784
LDL (mmol/L) 176 2.5 (0.9) 106 2.8 (0.9) 0.001 0.920
Triglycerides (mmol/L) 176 0.9 (0.4) 106 1.1 (0.7) <0.001 0.024
hs-CRP (mg/L) 138 1.3 (2.5) 244 2.3 (3.3) <0.001 0.974
Fasting glucose (mmol/L) 167 4.8 (0.5) 275 5.0 (0.5) <0.001 0.002
Fasting insulin (mIU/L) 167 7.4 (5.4) 275 9.2 (6.8) 0.003 0.798
OGTT glucose, 2 h (mmol/L) 109 4.9 (1.2) 234 5.6 (1.5) <0.001 0.104
OGTT insulin, 2 h (mIU/L) 109 29.0 (22.7) 234 62.2 (60.9) <0.001 0.020
OGTT mean glucose (mmol/L) 109 4.9 (0.7) 234 5.3 (0.9) <0.001 0.086
OGTT mean insulin (mIU/L) 109 18.2 (13.2) 234 35.9 (33.1) <0.001 0.045
HOMA-IR 167 1.6 (1.2) 275 2.1 (1.7) <0.001 0.507
Matsuda index 109 12.0 (8.3) 234 7.9 (6.5) <0.001 0.039
RBP4 (mg/L) 191 33.5 (18.3) 278 45.1 (24.0) <0.001 <0.001
Data shown as mean (s.d.). Statistically significant P values are in bold.
*P values adjusted for age and BMI using univariate general linear modelling.
BMI, body mass index; BP, blood pressure; DHEAS, dehydroepiandrosterone sulphate; FAI, free androgen index; HDL, high-density lipoprotein; HOMA-IR, 
homeostatic model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; OGTT, oral glucose 
tolerance test; PCOS, polycystic ovary syndrome; RBP4, retinol-binding protein 4; SHBG, sex hormone-binding globulin; WHR, waist-hip ratio.
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insulin resistance. In line with the present results, higher 
levels of RBP4 in women with PCOS have been reported 
in some (12, 29, 30) but not all studies (15, 16, 31).
Earlier studies have been carried out to investigate 
the association between RBP4 levels and various 
anthropometric indices including BMI and WHR. 
Consistent with our results, RBP4 levels have previously 
been shown to correlate positively with WHR, but not 
with BMI (12). In contrast, two studies revealed no 
correlation between RBP4 and WHR (13, 15). In addition, 
one study revealed that RBP4 levels were positively 
correlated with age in controls, but not in women with 
PCOS (32). Furthermore, consistent with the results of 
an earlier study (32), we found increased levels of RBP4 
in lean women with PCOS compared with controls with 
similar BMIs. In contrast, in another study no difference 
was found in the levels of RBP4 between lean women with 
and without PCOS, but higher levels in obese women with 
PCOS vs their controls (18).
Previous studies have shown that RBP4 is associated 
with fatty acid metabolism and there is a strong 
association between RBP4 and hypertriglyceridaemia (15, 
18, 29). However, some other studies have not revealed 
such an association (30, 32, 33). In the present study, 
triglyceride levels were positively correlated with those 
of RBP4 in younger women with PCOS, suggesting that 
elevated RBP4 levels might arise from altered triglyceride 
metabolism. Furthermore, larger adipocyte size in women 
with PCOS compared with non-PCOS women (34) may 
also play a role in increased RPB4 levels.
Elevated androgen levels are a key feature in women 
with PCOS, and the association of increased RBP4 levels 




Control PCOS P value* Control PCOS P value* Control PCOS P value*
Age 24.5 (2.9) 26.2 (2.7) <0.001 36.5 (2.8) 35.4 (2.7) 0.031 45.4 (3.3) 44.6 (3.3) NS
BMI (kg/m2) 23.0 (4.2) 26.1 (5.7) – 26.8 (5.5) 27.9 (5.6) – 25.8 (4.3) 28.4 (5.4) –
WHR 0.78 (0.05) 0.80 (0.07) NS 0.83 (0.09) 0.82 (0.07) NS 0.81 (0.06) 0.87 (0.09) 0.021
Systolic BP (mmHg) 112 (10) 115 (12) NS 121 (14) 123 (14) NS 124 (15) 130 (19) NS
Diastolic BP (mmHg) 68 (7) 71 (9) NS 76 (11) 78 (10) NS 78 (10) 82 (11) NS
Testosterone (nmol/L) 0.9 (0.4) 1.5 (0.6) <0.001 1.0 (0.4) 1.4 (0.8) <0.001 1.0 (0.5) 1.0 (0.4) NS
SHBG (nmol/L) 61.5 (23.9) 48.7 (23.5) 0.043 48.9 (21.7) 45.2 (22.1) NS 55.2 (25.1) 42.9 (21.6) NS
FAI 1.8 (1.4) 3.7 (2.2) <0.001 2.4 (1.6) 3.7 (2.6) 0.002 2.0 (0.9) 2.8 (1.7) 0.034
Androstenedione 
(nmol/L)
8.5 (4.6) 15.9 (8.7) <0.001 4.2 (1.8) 14.1 (8.5) 0.001 7.4 (3.0) 9.8 (3.7) NS
DHEAS (μmol/L) 3.5 (1.5) 5.2 (2.9) 0.008 5.0 (2.2) 4.2 (2.0) NS 3.3 (1.3) 4.0 (2.2) NS
Total cholesterol 
(mmol/L)
4.3 (0.9) 4.2 (0.7) NS 4.7 (0.8) 4.7 (0.9) NS 4.9 (1.0) 5.2 (1.0) NS
HDL (mmol/L) 1.5 (0.3) 1.4 (0.3) NS 1.6 (0.3) 1.4 (0.3) NS 1.7 (0.4) 1.7 (0.5) NS
LDL (mmol/L) 2.2 (0.9) 2.4 (0.6) NS 2.7 (0.7) 2.8 (0.9) NS 2.9 (1.0) 3.1 (0.9) NS
Triglycerides (mmol/L) 0.7 (0.3) 1.0 (0.5) 0.007 1.0 (0.4) 1.1 (0.7) NS 1.0 (0.5) 1.2 (0.7) NS
hs-CRP (mg/L) 1.2 (3.0) 2.5 (3.6) NS 1.5 (1.8) 2.2 (3.3) NS 1.4 (1.6) 1.8 (2.4) NS
Fasting glucose 
(mmol/L)
4.9 (0.5) 5.0 (0.5) NS 4.7 (0.5) 5.1 (0.6) 0.001 4.9 (0.5) 5.1 (0.7) NS
Fasting insulin (mIU/L) 7.1 (4.5) 9.0 (6.6) NS 8.6 (6.7) 9.8 (8.1) NS 6.8 (5.5) 9.0 (5.5) NS
OGTT glucose, 2 h 
(mmol/L)
4.8 (1.0) 5.5 (1.4) NS 4.7 (1.1) 5.8 (1.7) NS 5.1 (1.5) 5.4 (1.5) NS
OGTT insulin, 2 h 
(mIU/L)
34.5 (19.6) 61.8 (55.9) NS 22.0 (13.9) 66.9 (70.1) 0.040 26.8 (30.1) 57.7 (62.2) NS
OGTT mean glucose 
(mmol/L)
5.0 (0.6) 5.3 (0.8) NS 4.7 (0.6) 5.5 (1.0) 0.014 5.0 (0.9) 5.2 (0.9) NS
OGTT mean insulin 
(mIU/L)
21.1 (11.1) 35.4 (30.6) NS 14.9 (9.4) 38.9 (38.3) NS 16.9 (17.7) 33.6 (33.2) NS
HOMA-IR 1.5 (0.9) 2.1 (1.6) NS 1.8 (1.5) 2.3 (2.1) NS 1.5 (1.2) 2.0 (1.2) NS
Matsuda 9.0 (3.9) 7.6 (5.3) NS 13.6 (8.3) 7.8 (7.1) NS 15.1 (11.1) 8.5 (8.3) 0.046
RBP4 (mg/L) 27.1 (10.4) 47.7 (23.5) <0.001 38.1 (21.3) 42.1 (22.5) NS 40.5 (22.5) 42.3 (26.6) NS
Data shown as mean (s.d.).
*P values adjusted for BMI in individual age groups using univariate general linear modelling.
BMI, body mass index; BP, blood pressure; DHEAS, dehydroepiandrosterone sulphate; FAI, free androgen index; HDL, high-density lipoprotein; HOMA-IR, 
homeostatic model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; OGTT, oral glucose 
tolerance test; PCOS, polycystic ovary syndrome; RBP4, retinol-binding protein 4; SHBG, sex hormone-binding globulin; WHR, waist-hip ratio.
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with androgen levels could have implied that androgens 
may contribute to the increased serum levels of RBP4 
observed. However, this was not the case as we found 
no correlations between RBP4 and any of the measured 
androgens in the present study. This is in line with the 
results of other studies, which have revealed no association 
between elevated RBP4 levels and androgens (12, 17). 
Conversely, another study showed positive correlations 
between circulating concentrations of testosterone, 
DHEAS, A and RBP4 (35). In the present study, women 
with PCO + OA + HA had higher levels of serum RBP4 
when compared with those with PCO + OA. According to 
previous literature, phenotypes with HA are considered 
metabolically more severe compared with those without 
HA (36). However, it has to be noted that we could 
not compare serum RBP4 levels in women with other 
phenotypes (PCO + HA and OA + HA), as the numbers of 
such women were few.
A few previous studies have demonstrated that RBP4 
levels are strongly correlated with HOMA-IR in women 
with PCOS (11, 34). One study revealed that RBP4 levels 
correlated less strongly with insulin resistance in women 
with PCOS, although PCOS cases and controls showed no 
differences in RBP4 levels (16). These results are in contrast 
with those reported in other studies, which did not show 
any significant association between elevated RBP4 levels 
and insulin or insulin resistance as measured by HOMA 
(15, 35). Likewise, our results showed that increased 
RBP4 levels do not correlate with insulin resistance as 
measured by HOMA-IR, suggesting that increased RBP4 
levels observed in this study are not attributable to insulin 
resistance per se and serum concentrations of RBP4 might 
not directly affect glucose metabolism.
The heterogeneity of results obtained in studies of 
RBP4 in women with PCOS may be attributed to factors 
including different cohorts studied (obese vs non-obese; 
normoandrogenic vs hyperandrogenic; normal vs IGT; 
population-based vs hospital-based study population), 
differences in criteria in selection of women with PCOS 
(either Rotterdam or NIH criteria), methodological 
differences in measurements of RBP4 levels (Western blot 
vs ELISA) and differences in the methodologies used for 
assessing insulin resistance (OGTTs vs clamp studies) (15). 
In addition, there are different polymorphisms of RBP4, 
which may influence the association between RBP4 and 
insulin resistance (37).
There are several strengths in the present study. Our 
study included a well-characterised relatively large PCOS 
cohort ranging from a young age up to menopause, which 
enabled detailed evaluation of changes in hormonal 
and metabolic parameters, and their association with 
serum RBP4 levels. Even though the study subjects were 
recruited at different sites, all diagnoses of PCOS were 
made according to Rotterdam criteria. We addressed the 
issue of heterogeneity of results obtained in studies of 
RBP4 in women with PCOS by comparing serum levels 
of RBP4 in women with different phenotypes of PCOS, 
according to their androgen status and also according 
to their glucose tolerance. A limitation of the study is 
that we were unable to assess the effect of menstrual 
cycle changes on serum RBP4 levels, as the phase of the 
Figure 1
Concentrations of serum RBP4 in control women and in women with 
polycystic ovary syndrome in different age groups. The bars represent 
means and the error bars standard deviation. n denotes the number of 
subjects. *P < 0.001.
Figure 2
Concentrations of serum RBP4 in control women and in women with 
polycystic ovary syndrome in different BMI groups. The bars represent 
means and the error bars standard deviation. BMI in kg/m2. n denotes the 
number of subjects.
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menstrual cycle in 25% of the controls and 45% of the 
women with PCOS could not be ascertained, while the 
rest of the samples were taken in the follicular phase. 
However, the results remained the same when the 
samples taken in the follicular phase were analysed 
separately. Furthermore, the washout period for 
hormonal contraceptives was 2  months, which might 
have influenced the levels of RBP4, although an earlier 
study has shown that RBP4 levels are not influenced by 
oral contraceptive pills (15).
In conclusion, even though RBP4 has been shown 
to reflect disturbances in glucose metabolism in previous 
studies in the general population, and we found higher 
serum levels in younger women with PCOS, we were not 
able to establish a role of RBP4 in detecting metabolic 
derangements in PCOS in clinical practice.
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